RARE vs. CBAY, INSM, PBH, AXSM, ALKS, PRGO, BHVN, ALPN, HCM, and FOLD
Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include CymaBay Therapeutics (CBAY), Insmed (INSM), Prestige Consumer Healthcare (PBH), Axsome Therapeutics (AXSM), Alkermes (ALKS), Perrigo (PRGO), Biohaven (BHVN), Alpine Immune Sciences (ALPN), HUTCHMED (HCM), and Amicus Therapeutics (FOLD). These companies are all part of the "pharmaceutical preparations" industry.
CymaBay Therapeutics (NASDAQ:CBAY) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, profitability, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, risk and valuation.
CymaBay Therapeutics has a net margin of 0.00% compared to CymaBay Therapeutics' net margin of -139.70%. Ultragenyx Pharmaceutical's return on equity of -50.72% beat CymaBay Therapeutics' return on equity.
95.0% of CymaBay Therapeutics shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 7.0% of CymaBay Therapeutics shares are owned by company insiders. Comparatively, 6.8% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
CymaBay Therapeutics has a beta of 0.32, suggesting that its stock price is 68% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.65, suggesting that its stock price is 35% less volatile than the S&P 500.
In the previous week, Ultragenyx Pharmaceutical had 11 more articles in the media than CymaBay Therapeutics. MarketBeat recorded 12 mentions for Ultragenyx Pharmaceutical and 1 mentions for CymaBay Therapeutics. CymaBay Therapeutics' average media sentiment score of 0.41 beat Ultragenyx Pharmaceutical's score of 0.00 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.
Ultragenyx Pharmaceutical received 305 more outperform votes than CymaBay Therapeutics when rated by MarketBeat users. Likewise, 77.14% of users gave Ultragenyx Pharmaceutical an outperform vote while only 69.65% of users gave CymaBay Therapeutics an outperform vote.
CymaBay Therapeutics has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. CymaBay Therapeutics is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
CymaBay Therapeutics currently has a consensus price target of $28.65, indicating a potential downside of 11.79%. Ultragenyx Pharmaceutical has a consensus price target of $88.08, indicating a potential upside of 99.09%. Given CymaBay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than CymaBay Therapeutics.
Summary
Ultragenyx Pharmaceutical beats CymaBay Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultragenyx Pharmaceutical Competitors List
Related Companies and Tools
